- 4 Downloads
Immunotoxins directed against human immunodeficiency virus (HIV) may be of use in treating AIDS by eliminating HIV-infected cells that are actively secreting virus and serving as a nidus for the spread of the infection. These immunotoxins may be directed either toward viral structures expressed on the surface of cells or toward cell populations known to be sites of HIV replication.
The HIV envelope proteins gp120 and gp 41 are the major antigenic structures expressed on infected cells. They may be targeted with CD4 (the viral receptor) or with monoclonal antibodies. Activated lymphocytes expressing the interleukin-2 receptor are an important reservoir of HIV replication.
The efficacy of these immunotoxins has been established in vitro, and mechanisms of enhancement of immunotoxin action have been defined. A CD4-based immunotoxin has completed phase I clinical trials.
Unable to display preview. Download preview PDF.
- 7.Pincus SH. Immunotoxins. In Rosenberg M, et al., editors. Pharmacology of monoclonal antibodies. Berlin: Springer-Verlag, 1994. In pressGoogle Scholar
- 15.Berger EA, Clouse KA, Chaudhary VK, et al. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci USA 1989; 86: 9539–43PubMedCrossRefGoogle Scholar
- 33.Davey Jr RT, Boenning CM, Herpin BR, et al. A phase I study of recombinant CD4-Pseudomonas exotoxin (CD4-PE40) in HIV-infected individuals. Proceedings of the VIII International Conference on AIDS; 1992 Jul 19–24; Amsterdam, 1992: Mo8Google Scholar
- 40.Davey Jr RT, Boening CM, Herpin BR, et al. A phase I multidose trial of CD4-Pseudomonas exotoxin (sCD4-PE40) in HIV-1-infected individuals [abstract]. Proceedings of the IX International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993: 478Google Scholar